CUSIP 29772L108 · who reports it, how much, and how much it matters to them
22 of the 720 hedge fund managers we track reported shares of Eton Pharmaceuticals, Inc. (Nasdaq: ETON) on Form 13F for 30 June 2026. Between them they reported USD 146m. The largest position belongs to ECOR1 Capital, at USD 79m. The manager with the most riding on it is Cannell Capital, where it is 4.1% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | ECOR1 Capital3 funds on PPLI.com | USD 79m | 3.8% |
| 2 | Marshall Wace LLP84 funds on PPLI.com | USD 9m | 0.0% |
| 3 | Panoramic Capital4 funds on PPLI.com | USD 7.5m | 3.2% |
| 4 | D. E. Shaw & Co.15 funds on PPLI.com | USD 6.8m | 0.0% |
| 5 | Cannell Capital4 funds on PPLI.com | USD 6.2m | 4.1% |
| 6 | Prospect Capital Advisors2 funds on PPLI.com | USD 5.7m | 2.6% |
| 7 | Aristides Capital2 funds on PPLI.com | USD 5.3m | 1.0% |
| 8 | Prelude Capital Management9 funds on PPLI.com | USD 5m | 0.4% |
| 9 | Two Sigma Investments35 funds on PPLI.com | USD 4.2m | 0.0% |
| 10 | Walleye Capital8 funds on PPLI.com | USD 3.1m | 0.0% |
| 11 | Diametric Capital2 funds on PPLI.com | USD 2.6m | 0.3% |
| 12 | Squarepoint Ops7 funds on PPLI.com | USD 2.2m | 0.0% |
| 13 | Boothbay Fund Management2 funds on PPLI.com | USD 2.1m | 0.0% |
| 14 | Renaissance Technologies13 funds on PPLI.com | USD 1.9m | 0.0% |
| 15 | Citadel Advisors32 funds on PPLI.com | USD 1.8m | 0.0% |
| 16 | POINT72 Asset Management17 funds on PPLI.com | USD 1.6m | 0.0% |
| 17 | Aquatic Capital Management3 funds on PPLI.com | USD 1.6m | 0.1% |
| 18 | Brevan Howard Capital Management39 funds on PPLI.com | USD 288,000 | 0.0% |
| 19 | Voleon Capital Management13 funds on PPLI.com | USD 262,000 | 0.0% |
| 20 | Jain Global1 fund on PPLI.com | USD 261,000 | 0.0% |
| 21 | Persistent Asset Partners10 funds on PPLI.com | USD 90,247 | 0.0% |
| 22 | The Quarry1 fund on PPLI.com | USD 941 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Cannell Capital | USD 6.2m | 4.1% |
| 2 | ECOR1 Capital | USD 79m | 3.8% |
| 3 | Panoramic Capital | USD 7.5m | 3.2% |
| 4 | Prospect Capital Advisors | USD 5.7m | 2.6% |
| 5 | Aristides Capital | USD 5.3m | 1.0% |
| 6 | Prelude Capital Management | USD 5m | 0.4% |
| 7 | Diametric Capital | USD 2.6m | 0.3% |
| 8 | Aquatic Capital Management | USD 1.6m | 0.1% |
| 9 | Boothbay Fund Management | USD 2.1m | 0.0% |
| 10 | Persistent Asset Partners | USD 90,247 | 0.0% |
Eton Pharmaceuticals, Inc. trades under the symbol ETON on the Nasdaq. Its CUSIP, the code used on Form 13F, is 29772L108.
22 of the 720 hedge fund managers PPLI.com tracks reported Eton Pharmaceuticals, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by ECOR1 Capital (USD 79m), Marshall Wace LLP (USD 9m), Panoramic Capital (USD 7.5m), D. E. Shaw & Co. (USD 6.8m) and Cannell Capital (USD 6.2m).
22 managers in our coverage reported it, and between them they run 306 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Cannell Capital, where the position was 4.1% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Eton Pharmaceuticals, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.